Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Role of tyrosine kinase inhibitors in cancer therapy.J Pharmacol Exp Ther. 2005; 315: 971-979
- Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways.Science. 1986; 233: 859-866
- Raf kinases in cancer-roles and therapeutic opportunities.Oncogene. 2011; 30: 3477-3488
- Driver mutations in the mitogen-activated protein kinase pathway: the seeds of good and evil.Br J Dermatol. 2018; 178: 26-27
- Hallmarks of cancer: the next generation.Cell. 2011; 144: 646-674
- Protein kinase activity associated with the avian sarcoma virus src gene product.Proc Natl Acad Sci U S A. 1978; 75: 2021-2024
- Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C.Biochemistry. 1984; 23: 5036-5041
- A flow-based synthesis of Imatinib: the API of Gleevec.Chem Commun. 2010; 46: 2450-2452
- Sunitinib malate for the treatment of solid tumours: a review of current clinical data.Expert Opin Investig Drugs. 2006; 15: 553-561
- Sorafenib in advanced hepatocellular carcinoma.N Engl J Med. 2008; 359: 378-390
- Epidermal growth factor receptor mutation (EGFR) testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer: an evidence-based analysis.Ont Health Technol Assess Ser. 2010; 10: 1-48
- Hepatocellular carcinoma.N Engl J Med. 2019; 380: 1450-1462
- Experimental models of hepatocellular carcinoma in mice.Surg Chronicles. 2013; 18: 134-138
- Pivotal role of mTOR signaling in hepatocellular carcinoma.Gastroenterology. 2008; 135https://doi.org/10.1053/j.gastro.2008.08.008
- Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery.Ann Surg Oncol. 2003; 10: 355-362
- Kinase (MEK)-MAPK in hepatocellular carcinoma : its role in tumor progression and apoptosis.BMC Gastroenterol. 2003; 19: 1-21
- Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.J Clin Oncol. 2005; 23: 965-972
- Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.J Clin Oncol. 2006; 24: 4293-4300
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol. 2009; 10: 25-34
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies.J Hepatol. 2017; 67: 999-1008
- Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.Clin Cancer Res. 2012; 18: 2290-2300
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet. 2018; 391: 1163-1173
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study.J Hepatol. 2016; 65: 1140-1147
- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.Cancer. 2010; 116: 4590-4596
- Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.J Hepatol. 2013; 59: 1014-1021
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.J Hepatol. 2014; 61https://doi.org/10.1016/j.jhep.2014.03.030
- Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.Aliment Pharmacol Ther. 2019; 49: 482-491
- Complete response under sorafenib in patients with hepatocellular carcinoma: relationship with dermatologic adverse events.Hepatology. 2018; 67: 612-622
- Small-molecule inhibitor sorafenib regulates immunoreactions by inducing survival and differentiation of bone marrow cells.Innate Immun. 2016; 22: 493-502
- Sorafenib induces pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma.Hepatology. 2019; 70: 1280-1297
- Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.Nat Genet. 2012; 44: 694-698
- Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.J Clin Oncol. 2013; 31: 4067-4075
- Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.J Clin Oncol. 2013; 31: 3517-3524
- Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.J Clin Oncol. 2013; 31: 3509-3516
- Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.J Clin Oncol. 2015; 33: 172-179
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.Lancet Oncol. 2018; 19: 682-693
- Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization.Acta Radiol. 2008; 49: 523-529
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial.J Hepatol. 2016; 64: 1090-1098
- Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial.Hepatology. 2014; 60: 1697-1707
- Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.Gut. 2019; https://doi.org/10.1136/gutjnl-2019-318934
- Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.Hepatology. 2013; 58: 2023-2031
- Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial.J Hepatol. 2019; 70: 684-691
- The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the Soramic trial palliative cohort.J Hepatol. 2018; 68: S102
- Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma.JAMA. 2010; 304: 2154
- Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial.JAMA Oncol. 2019; 5: 1582-1588
- SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.J Clin Oncol. 2015; 33: 559-566
- Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.Oncology. 2012; 82: 67-74
- A randomized phase II open label multi-institution study of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) in the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC).J Clin Oncol. 2015; 33: 337
- Control of the immune response by pro-angiogenic factors.Front Oncol. 2014; https://doi.org/10.3389/fonc.2014.00070
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.PLoS One. 2019; 14: e0212513
- Assessment of treatment efficacy in hepatocellular carcinoma: response rate, delay in progression or none of them.J Hepatol. 2017; 66: 1114-1117
- Insights into the success and failure of systemic therapy for hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol. 2019; 16: 617-630
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.J Gastroenterol. 2017; 52: 512-519
- BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res. 2004; 64: 7099-7109
- Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.Int J Cancer. 2011; 129: 245-255
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2017; 389: 56-66
- Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.J Clin Oncol. 2018; 36: 412
- The receptor tyrosine kinase AXL in cancer progression.Cancers (Basel). 2016; 8https://doi.org/10.3390/cancers8110103
- Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.Cancer Sci. 2016; 107: 407-416
- Evolution of ramucirumab in the treatment of cancer—a review of literature.J Oncol Pharm Pract. 2017; 23: 525-539
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.Lancet Oncol. 2015; 16: 859-870
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2019; 20: 282-296
- Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): outcomes from two randomized phase 3 studies (REACH, REACH2).J Clin Oncol. 2019; 37: 4073
- Targeted therapy for hepatocellular carcinoma: challenges and opportunities.Cancer Lett. 2019; 460: 1-9
- In vivo acquired sorafenib-resistant patient-derived tumor model displays alternative angiogenic pathways, multi-drug resistance and chromosome instability.Oncol Lett. 2018; 16: 3439-3446
- Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.Mol Cancer Ther. 2012; 11: 452-463
- Reviewing RECIST in the era of prolonged and targeted therapy.J Thorac Oncol. 2018; 13: 154-164
- Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.Semin Liver Dis. 2010; 30: 052-060
- EASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol. 2018; 69: 182-236
- Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.J Hepatol. 2010; 53: 558-567
- Weak correlation of overall survival and time to progression in advanced hepatocellular carcinoma.J Clin Oncol. 2017; 35 (abstract 233)
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.N Engl J Med. 2020; 382: 1894-1905
Article info
Publication history
Published online: September 05, 2020
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
